• Consensus Rating: Hold
  • Consensus Price Target: $19.43
  • Forecasted Upside: 128.30%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.51
▲ +0.04 (0.47%)

This chart shows the closing price for CYRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cryoport Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYRX

Analyst Price Target is $19.43
▲ +128.30% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Cryoport in the last 3 months. The average price target is $19.43, with a high forecast of $28.00 and a low forecast of $16.00. The average price target represents a 128.30% upside from the last price of $8.51.

This chart shows the closing price for CYRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 investment analysts is to hold stock in Cryoport. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/19/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00Low
5/3/2024B. RileyDowngradeBuy ➝ Neutral$22.00 ➝ $19.00Low
4/4/2024Jefferies Financial GroupInitiated CoverageBuy$17.00 ➝ $21.00Low
3/15/2024UBS GroupBoost TargetNeutral ➝ Neutral$14.50 ➝ $17.00N/A
3/13/2024StephensReiterated RatingEqual Weight ➝ Equal Weight$17.00Low
3/13/2024Needham & Company LLCLower TargetBuy$19.00 ➝ $18.00Low
1/18/2024Needham & Company LLCBoost TargetBuy ➝ Buy$18.00 ➝ $19.00Low
8/17/2023Morgan StanleyInitiated CoverageEqual Weight$16.00Low
8/10/2023BTIG ResearchLower Target$33.00 ➝ $28.00N/A
8/10/2023Needham & Company LLCLower TargetBuy ➝ Buy$30.00 ➝ $21.00Low
8/10/2023StephensDowngradeOverweight ➝ Equal Weight$15.00Low
7/18/2023UBS GroupDowngradeBuy ➝ Neutral$28.00 ➝ $17.00Low
7/17/2023StephensDowngradeOverweight ➝ Equal WeightLow
7/17/2023BTIG ResearchLower Target$40.00 ➝ $33.00Low
7/13/2023SVB LeerinkDowngradeOutperform ➝ Market PerformLow
7/13/2023B. RileyLower Target$30.00 ➝ $22.00Low
7/13/2023SVB SecuritiesDowngradeOutperform ➝ Market Perform$30.00 ➝ $10.00Low
4/21/2023Needham & Company LLCReiterated RatingBuy$30.00Low
2/24/2023Needham & Company LLCBoost TargetBuy$28.00 ➝ $30.00Low
12/8/2022KeyCorpLower TargetOverweight$40.00 ➝ $30.00Low
11/16/2022B. RileyLower TargetBuy$55.00 ➝ $30.00Low
11/4/2022KeyCorpLower TargetOverweight$52.00 ➝ $40.00Low
11/4/2022Needham & Company LLCLower TargetBuy$49.00 ➝ $28.00Low
11/4/2022SVB LeerinkLower TargetOutperform$45.00 ➝ $28.00Low
7/12/2022Needham & Company LLCBoost TargetBuy$41.00 ➝ $42.00N/A
6/17/2022Needham & Company LLCReiterated RatingBuy$41.00Low
5/17/2022B. RileyLower Target$61.00 ➝ $55.00Low
5/6/2022BTIG ResearchLower Target$95.00 ➝ $60.00Medium
5/6/2022KeyCorpLower Target$92.00 ➝ $52.00Medium
5/3/2022Roth CapitalLower Target$90.00 ➝ $67.00High
4/13/2022Needham & Company LLCReiterated RatingBuy$45.00Low
3/2/2022B. RileyLower Target$94.00 ➝ $70.00Low
2/25/2022SVB LeerinkBoost TargetOutperform$75.00 ➝ $92.00High
2/25/2022Needham & Company LLCLower TargetBuy$93.00 ➝ $45.00High
1/19/2022Roth CapitalUpgradeNeutral ➝ Buy$90.00High
11/11/2021B. RileyReiterated RatingBuyMedium
11/5/2021Roth CapitalDowngradeBuy ➝ Neutral$78.00 ➝ $90.00High
11/5/2021Needham & Company LLCBoost TargetBuy$79.00 ➝ $93.00High
11/5/2021KeyCorpBoost TargetOverweight$75.00 ➝ $92.00High
10/26/2021BTIG ResearchBoost TargetPositive ➝ Buy$80.00 ➝ $95.00Low
10/19/2021B. RileyReiterated RatingBuyHigh
8/6/2021Roth CapitalBoost TargetBuy$72.00 ➝ $78.00High
8/6/2021Needham & Company LLCBoost TargetBuy$77.00 ➝ $79.00High
7/16/2021BTIG ResearchInitiated CoverageBuy$80.00Low
5/5/2021Needham & Company LLCBoost TargetBuy$73.00 ➝ $77.00High
3/15/2021UBS GroupInitiated CoverageBuy$84.00Medium
3/2/2021SVB LeerinkBoost TargetOutperform$50.00 ➝ $75.00High
3/2/2021Needham & Company LLCReiterated RatingBuy$73.00High
2/10/2021B. RileyBoost TargetBuy$69.00 ➝ $81.00Low
1/19/2021KeyCorpBoost TargetOverweight$54.00 ➝ $75.00Low
1/14/2021Roth CapitalBoost TargetBuy$60.00 ➝ $72.00High
1/12/2021B. RileyBoost TargetBuy$66.00 ➝ $69.00Medium
11/9/2020KeyCorpInitiated CoverageOverweight$54.00High
11/6/2020Needham & Company LLCBoost TargetBuy$44.00 ➝ $45.00High
9/10/2020B. RileyBoost Target$45.00 ➝ $66.00Medium
8/24/2020Roth CapitalBoost TargetBuy$42.00 ➝ $50.00High
8/24/2020Needham & Company LLCBoost TargetBuy$37.00 ➝ $44.00High
8/24/2020StephensBoost TargetOverweight$38.00 ➝ $44.00High
8/7/2020Needham & Company LLCBoost TargetBuy$23.00 ➝ $37.00High
7/21/2020SVB LeerinkReiterated RatingOutperformMedium
7/7/2020B. RileyBoost Target$24.00 ➝ $40.00Low
5/11/2020Roth CapitalBoost Target$25.00 ➝ $30.00Medium
5/8/2020SVB LeerinkBoost TargetOutperform$24.00 ➝ $25.00High
4/7/2020B. RileyReiterated RatingBuy$24.00High
3/26/2020Needham & Company LLCReiterated RatingBuy$23.00Low
3/6/2020Janney Montgomery ScottReiterated RatingBuy$25.00 ➝ $25.00Medium
3/6/2020Needham & Company LLCBoost TargetBuy$22.00 ➝ $23.00High
2/13/2020B. RileyLower TargetBuy$26.00 ➝ $24.00Medium
1/13/2020Needham & Company LLCLower TargetBuy$24.00 ➝ $22.00High
1/10/2020B. RileyInitiated CoverageBuy$26.00High
1/7/2020StephensInitiated CoverageOverweight$21.00High
7/19/2019B. RileySet TargetBuy$26.00N/A
(Data available from 7/19/2019 forward)

News Sentiment Rating

1.11 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 7 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/20/2024
  • 14 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/21/2024
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2024
  • 12 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
5/20/2024
  • 8 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/19/2024

Current Sentiment

  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Cryoport logo
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
Read More

Today's Range

Now: $8.51
Low: $8.19
High: $8.54

50 Day Range

MA: $9.55
Low: $5.55
High: $14.05

52 Week Range

Now: $8.51
Low: $5.32
High: $20.10

Volume

1,087,773 shs

Average Volume

1,129,030 shs

Market Capitalization

$419.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Cryoport?

The following Wall Street sell-side analysts have issued research reports on Cryoport in the last twelve months: B. Riley, BTIG Research, Jefferies Financial Group Inc., Morgan Stanley, Needham & Company LLC, Stephens, and UBS Group AG.
View the latest analyst ratings for CYRX.

What is the current price target for Cryoport?

7 Wall Street analysts have set twelve-month price targets for Cryoport in the last year. Their average twelve-month price target is $19.43, suggesting a possible upside of 128.3%. BTIG Research has the highest price target set, predicting CYRX will reach $28.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $16.00 for Cryoport in the next year.
View the latest price targets for CYRX.

What is the current consensus analyst rating for Cryoport?

Cryoport currently has 4 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CYRX, but not buy more shares or sell existing shares.
View the latest ratings for CYRX.

What other companies compete with Cryoport?

How do I contact Cryoport's investor relations team?

Cryoport's physical mailing address is 112 Westwood Place Suite 350, Brentwood TN, 37027. The company's listed phone number is (949) 470-2300 and its investor relations email address is [email protected]. The official website for Cryoport is www.cryoport.com. Learn More about contacing Cryoport investor relations.